Research programme: RNA targeting therapeutics - Syntara Limited/Santen
Alternative Names: Nova 21048Latest Information Update: 13 Dec 2023
At a glance
- Originator Novagali Pharma; Topigen Pharmaceuticals
- Developer Santen S.A.S.; Syntara Limited
- Class Oligonucleotides
- Mechanism of Action Chemokine CCL11 inhibitors; RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Allergic conjunctivitis; Allergic rhinitis